1GLOBAL
22.1.2024 18:18:25 CET | Business Wire | Press release
Kuwait-based low-cost airline Jazeera Airways has partnered with London headquartered Telco 1GLOBAL to become the first airline in the MENA region to launch its own travel eSIM offering. The collaboration will enable Jazeera passengers to communicate cost-effectively and avoid expensive roaming costs when travelling. At the same time, it will serve to strengthen Jazeera Airways´ customer loyalty and satisfaction, while boosting ancillary revenues.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240122511628/en/
Yousef Al Qatami, Chief of Staff at 1GLOBAL. (Source: 1GLOBAL)
Leveraging the power of eSIM
Through the partnership 1GLOBAL will integrate its consumer eSIM technology into Jazeera Airlines' service offering. The process will begin with the implementation of a Jazeera branded QR code and web-based solution, followed by a full-fledged integration into the Jazeera Airways app. The white label solution allows Jazeera to offer eSIM services while maintaining the airlines own look and feel.
Andrew Ward, Vice President Marketing & Customer Experience at Jazeera Airways, says: "We are delighted to be able to offer the 1GLOBAL service to our passengers. We are always looking for ways to reduce travel costs and the 1GLOBAL eSIM offers low call rates for travellers across the Jazeera network."
A benefit for both the airline and its passengers
The roaming solution will be marketed through various communication channels including social media, in-flight magazines, email confirmations and promotional material in airport terminals. The partnership offers benefits for both travellers and Jazeera Airways. By activating the 1GLOBAL roaming eSIM, travellers will be able to stay connected more cost effectively than if they were using their standard roaming plan. They will also have access to high quality 5G & 4G coverage in almost all countries with plenty of flexible tariff options to choose from. Jazeera Airways on the other hand hopes to increase customer loyalty by providing this value-added service. This initiative not only distinguishes Jazeera Airways from its competitors through innovative offerings, but it also aims to increase revenue through ancillary services.
Yousef Al Qatami, Chief of Staff at 1GLOBAL, emphasises: "We are very proud to have supported the Jazeera Airways team in being the first airline in the MENA region to launch an eSIM offering. We are confident in the region's growth trajectory and hope to bring the benefits of eSIM to more local businesses and customers."
About Jazeera Airways
Jazeera Airways operates commercial and cargo flights out of its Jazeera Terminal T5 at Kuwait International Airport. The airline flies to over 64 popular destinations across the Middle East, Central and South Asia, Africa and Europe comprising high-demand business, leisure, religious and weekend destinations.
About 1GLOBAL
Founded in 2022, 1GLOBAL acquired a group of telco assets operational since 2006, including an internationally recognized GSMA-accredited global mobile network. Headquartered in London with our R&D hub in Lisbon, we have grown to over 400 employees across 12 countries and have been granted the status of fully regulated MVNO in 9 of them.
As innovators in eSIM-based GSM mobile services, 1GLOBAL caters to both businesses and individuals with products including mobile call and SMS recording services for businesses, remote SIM provisioning, IOT solutions, Telco-as-a-Service for travel companies, and affordable roaming for everyday consumers.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240122511628/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
